195 related articles for article (PubMed ID: 22286070)
1. Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases.
Rasche L; Bernard C; Topp MS; Kapp M; Duell J; Wesemeier C; Haralambieva E; Maeder U; Einsele H; Knop S
Ann Hematol; 2012 Jul; 91(7):1031-7. PubMed ID: 22286070
[TBL] [Abstract][Full Text] [Related]
2. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry.
Alegre A; Granda A; Martínez-Chamorro C; Díaz-Mediavilla J; Martínez R; García-Laraña J; Lahuerta JJ; Sureda A; Bladé J; de la Rubia J; Fernández-Rañada JM; San Miguel J; ; ;
Haematologica; 2002 Jun; 87(6):609-14. PubMed ID: 12031917
[TBL] [Abstract][Full Text] [Related]
3. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
4. Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients.
Moulopoulos LA; Dimopoulos MA; Kastritis E; Christoulas D; Gkotzamanidou M; Roussou M; Koureas A; Migkou M; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Gika D; Koutoulidis V; Terpos E
Am J Hematol; 2012 Sep; 87(9):861-4. PubMed ID: 22641455
[TBL] [Abstract][Full Text] [Related]
5. Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome.
Minnema MC; van de Donk NW; Zweegman S; Hegenbart U; Schonland S; Raymakers R; Zijlmans JM; Kersten MJ; Bos GM; Lokhorst HM
Bone Marrow Transplant; 2008 May; 41(9):779-84. PubMed ID: 18195681
[TBL] [Abstract][Full Text] [Related]
6. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk Cytogenetic Features.
Rasche L; Röllig C; Stuhler G; Danhof S; Mielke S; Grigoleit GU; Dissen L; Schemmel L; Middeke JM; Rücker V; Schreder M; Schetelig J; Bornhäuser M; Einsele H; Thiede C; Knop S
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1988-1996. PubMed ID: 27590108
[TBL] [Abstract][Full Text] [Related]
8. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
Tan D; Teoh G; Lau LC; Lim A; Lim TH; Yap KC; Premalatha P; Lao ZT; Wee N; Choo C; Wee HC; Su S; Lee YS; Lee LH; Hwang W; Goh YT
Am J Hematol; 2010 Oct; 85(10):752-6. PubMed ID: 20721886
[TBL] [Abstract][Full Text] [Related]
9. Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation.
Inamoto Y; Kurahashi S; Imahashi N; Fukushima N; Adachi T; Kinoshita T; Tsushita K; Miyamura K; Naoe T; Sugiura I
Am J Hematol; 2009 May; 84(5):283-6. PubMed ID: 19338045
[TBL] [Abstract][Full Text] [Related]
10. Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome.
Zeiser R; Deschler B; Bertz H; Finke J; Engelhardt M
Bone Marrow Transplant; 2004 Dec; 34(12):1057-65. PubMed ID: 15516937
[TBL] [Abstract][Full Text] [Related]
11. Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma.
Terpos E; Rezvani K; Basu S; Milne AE; Rose PE; Scott GL; Rahemtulla A; Samson D; Apperley JF
Eur J Haematol; 2005 Nov; 75(5):376-83. PubMed ID: 16191086
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of thalidomide in refractory multiple myeloma.
Singhal S; Mehta J; Desikan R; Ayers D; Roberson P; Eddlemon P; Munshi N; Anaissie E; Wilson C; Dhodapkar M; Zeddis J; Barlogie B
N Engl J Med; 1999 Nov; 341(21):1565-71. PubMed ID: 10564685
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic transplantation for multiple myeloma: late relapse may occur as localised lytic lesion/plasmacytoma despite ongoing molecular remission.
Byrne JL; Fairbairn J; Davy B; Carter IG; Bessell EM; Russell NH
Bone Marrow Transplant; 2003 Feb; 31(3):157-61. PubMed ID: 12621475
[TBL] [Abstract][Full Text] [Related]
14. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance.
Jaksic W; Trudel S; Chang H; Trieu Y; Qi X; Mikhael J; Reece D; Chen C; Stewart AK
J Clin Oncol; 2005 Oct; 23(28):7069-73. PubMed ID: 16129840
[TBL] [Abstract][Full Text] [Related]
16. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.
Majolino I; Vignetti M; Meloni G; Vegna ML; Scimè R; Tringali S; Amaddii G; Coser P; Tribalto M; Raimondi R; Bergonzi C; Sajeva MR; Sica S; Ferrando F; Messina G; Mandelli F
Haematologica; 1999 Sep; 84(9):844-52. PubMed ID: 10477460
[TBL] [Abstract][Full Text] [Related]
17. Benefit and timing of second transplantations in multiple myeloma: clinical findings and methodological limitations in a European Group for Blood and Marrow Transplantation registry study.
Morris C; Iacobelli S; Brand R; Bjorkstrand B; Drake M; Niederwieser D; Gahrton G;
J Clin Oncol; 2004 May; 22(9):1674-81. PubMed ID: 15037597
[TBL] [Abstract][Full Text] [Related]
18. Outcome of very late relapse in children with acute lymphoblastic leukemia.
Rizzari C; Valsecchi MG; Aricò M; Miniero R; Messina C; De Rossi G; Testi AM; Mura R; Galimberti S; Biondi A; Locatelli F; Conter V
Haematologica; 2004 Apr; 89(4):427-34. PubMed ID: 15075076
[TBL] [Abstract][Full Text] [Related]
19. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women.
Pentheroudakis G; Fountzilas G; Bafaloukos D; Koutsoukou V; Pectasides D; Skarlos D; Samantas E; Kalofonos HP; Gogas H; Pavlidis N
Breast Cancer Res Treat; 2006 Jun; 97(3):237-44. PubMed ID: 16322882
[TBL] [Abstract][Full Text] [Related]
20. Treatment of multiple myeloma.
San Miguel JF; Bladé Creixenti J; García-Sanz R
Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
